HPV9 Vaccine for the Prevention of Human Papillomavirus-Related Cancers.
Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) in the United States, with approximately 79 million Americans currently infected. Persistent infection with HPV has been identified as the causative factor in the development of invasive cervical cancer as well as other oral and genital cancers in women and men. The quadravalent HPV4 vaccine has been available since 2006. In December 2014, the U.S. Food and Drug Administration (FDA) approved the HPV9 vaccine that provides coverage for five additional oncogenic strains of HPV that are not included in the first generation vaccine.
Holly B
HB
Fontenot
Heidi Collins
HC
Fantasia
D005260:Female; D006266:Health Education / Q000379:methods; D006801:Humans; D008297:Male; D027383:Papillomaviridae / Q000472:pathogenicity; D030361:Papillomavirus Infections / Q000517:prevention & control* / Q000628:therapy; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000517:prevention & control*
D053918:Papillomavirus Vaccines
HPV; HPV9 vaccine; human papillomavirus; sexually transmitted infection